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Abstract
Objectives of this study were to evaluate glomerular filtration rate (GFR), renal structural changes and proteinuria in aged
Beagle dogs before and after hydrocortisone (HC) administration. Eleven Beagle dogs $10 years old were treated with
either hydrocortisone (HC group, n=6) or placebo (control group, n=5). Urinary markers, GFR and kidney biopsies were
evaluated before (T0), during (T16 wks) and after discontinuing HC administration (T24 wks). Results indicate that HC
administration causes a significant increase in GFR. At all time points except T16 wks, proteinuria was higher in the control
group than in the HC group, and there was no significant difference in urinary markers between groups. At T16 wks,
proteinuria, urinary albumin-to-creatinine (c) ratio, immunoglobulin G/c and retinol-binding protein/c were higher
compared to baseline in the HC group. At T0, rare to mild renal lesions were detected in all HC dogs and rare to moderate
changes in all control dogs. Glomerulosclerosis progressed in both groups until T24 wks. Tubular atrophy was detected in
three HC dogs at T16 wks and T24 wks, but also in five control dogs throughout the study. At every time point, five HC dogs
and all control dogs had rare to moderate interstitial inflammation. Rare to mild interstitial fibrosis was found in up to three
HC dogs at T16 wks and T24 wks, and severe fibrosis in one HC dog at T24 wks. Up to four control dogs had rare to mild
fibrosis at all time points. These findings indicate that clinically healthy, aged Beagle dogs may have considerable renal
lesions and proteinuria, which could have implications for experimental or toxicological studies. Additional research is
needed to elucidate glucocorticoid effects on renal structure, but functional changes such as hyperfiltration and proteinuria
warrant attention to kidney function of canine patients with Cushing’s syndrome or receiving exogenous glucocorticoids.
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Introduction
Proteinuria has been described in 44–75% of dogs with
Cushing’s syndrome and sometimes persists or even develops
after successful treatment of hypercortisolism [1,2]. An increased
urinary albumin excretion has also been demonstrated in more
than 80% of human Cushing patients prior to treatment of
hypercortisolism [3]. Whereas short-term administration of
exogenous glucocorticoids (GC) seems to increase GFR in humans
and dogs, one study indicates a decreased glomerular filtration rate
(GFR) in people with Cushing’s syndrome and suggests that renal
compromise in these patients warrants more attention [4,5,6].
Therefore, human and canine Cushing patients could be
considered at risk for renal complications, but information about
effects of GC on renal function is scarce.
Canine endogenous hypercortisolism or Cushing’s syndrome is
considered a good animal model for its human counterpart,
because of similarities in the pathogenesis : 80–85% of cases are
caused by a pituitary tumor and ACTH-dependent, while 15–20%
are ACTH-independent [7]. Moreover, middle-aged to old
individuals are typically affected in both species and similar
clinical signs include fatigue, weight gain and central obesity with
muscle atrophy of the limbs, polyuria, polydipsia and polyphagia,
with the latter three being most pronounced in the dog [8,9].
Previous experimental studies evaluating GC effects on renal
function often differed from the in vivo situation in spontaneous
Cushing’s syndrome. For example, many experiments included
young animals [10,11]. Aging itself has marked effects on renal
structure and function in humans, but also in laboratory animals,
dogs and cats [12,13,14,15,16]. Therefore, in aged individuals GC
will act on kidneys with an already decreased renal functional
reserve [17,18].
In addition to serum renal markers and GFR, urinary markers
are gaining interest in veterinary medicine, because of their
potential for early detection of renal dysfunction and ability to
localize the insult to a particular part of the nephron [19,20,21].
These markers include high molecular weight (HMW) proteins
such as immunoglobulin G (IgG), intermediate (I)MW proteins
such as albumin (ALB), low (L)MW proteins such as retinol-
binding protein (RBP) and urinary enzymes such as N-acetyl-b-D-
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higher filtration of ALB and in more advanced stages to presence
of IgG in the ultrafiltrate [24]. Tubular dysfunction is reflected by
urinary loss of RBP and NAG, due to disturbed reabsorption or
increased protein trafficking and structural damage of tubule cells,
respectively [25,26].
Information about GC effects on renal function and morphol-
ogy is rare, and often limited to case reports, despite their frequent
therapeutic use and the occurrence of Cushing’s syndrome in
humans and dogs [11,27,28,29,30]. Therefore, the objectives of
this study were to evaluate GFR, renal light microscopic and
ultrastructural changes, and proteinuria in old Beagle dogs before
and after administration of hydrocortisone.
Materials and Methods
Animals
This study was approved by the Ethical Committee of Ghent
University (EC: 2008/146). Eleven female spayed Beagle dogs, age
8.4 to 11 years (median: 10 years), with a body weight ranging
from 10.9 to 14 kg (median 12.9 kg) were included in the study.
Dogs were housed in pairs in two adjacent indoor kennels of
2.6 m
2 each, with free access to water, fed a standard dry food
twice a day (Hill’s science plan, Hill’s Pet Nutrition, Breda, The
Netherlands, 25.0% protein, 15.3% fat, 52.0% carbohydrates,
2.6% fiber), and allowed outdoor activity in a secured area. They
were judged healthy based on physical examination, hematology,
biochemistry profile, abdominal ultrasound and two consecutive
morning urinary corticoid-to-creatinine ratio’s (,10
*10
26)t o
exclude endogenous Cushing’s syndrome. A urinalysis consisting
of sediment and dipstick analysis, urine specific gravity (USG),
urinary protein-to-creatinine ratio (UPC), and bacterial culture
were performed, but proteinuria (UPC.0.5) was not an exclusion
criterion.
Study design
Five dogs were randomly assigned to the placebo group (control
group) and six to the hydrocortisone treatment group (HC group).
After baseline sampling (T0), the control group received a gelatin
capsule containing lactose and the HC-group received a capsule
containing lactose and a median dose of 9.6 mg/kg HC (range
from 8.7 to 11.0 mg/kg) every 12 hours (h). Hydrocortisone was
used because it is the synthetic glucocorticoid most closely
resembling endogenous cortisol and dosage was based on two
previous publications [10,11]. Dogs were monitored for develop-
ment of clinical signs of GC excess such as polyuria, polydipsia and
polyphagia, and for skin abnormalities using a scoring sheet.
Treatment period was 16 weeks (end of treatment period:
T16 wks), then the HC dose was tapered over 4 weeks (1 week
10 mg/kg once a day, two weeks 5 mg/kg once a day, and one
week 2.5 mg/kg once a day, end of tapering period: T20 wks) and
the study ended four weeks after completely stopping treatment
(end of study: T24 wks). Plasma exogenous creatinine-iohexol
clearance tests (PEC-ICT), kidney biopsies and urine sampling
were performed in both groups at baseline, at T16 wks and at
T24 wks. Blood and urine samples were additionally collected
during treatment after 4 wks (T4 wks) and at T20 wks.
At T16 wks and T24 wks, an ACTH-stimulation test was
performed in all dogs by collecting serum for measurement of
cortisol before and 60 minutes (min) after intramuscular injection
of 0.25 mg of synthethic ACTH (Synacthen, tetracosactide hexa-
acetate, Novartis Pharma, Vilvoorde, Belgium). Cortisol concen-
trations were measured using an immunoassay validated for use in
the dog (Architect I 2000 System, Abbott, Waver, Belgium).
Sampling methods
Morning urine samples were taken by cystocentesis (10 mL, 22
G needle). Urinary dipstick analysis (Combur stick, Roche
Diagnostics, Burgess Hill, UK), urine specific gravity (USG),
urinary protein-to-creatinine ratio (UPC), sediment analysis and
bacterial culture were performed. After centrifugation, the urine
supernatant was stored at 280uC until analysis of urinary markers.
Plasma exogenous creatinine-iohexol clearance test
All dogs were fasted for at least 10 h prior to the test day and fed
immediately after ending the sampling period. Water was
provided ad libitum. Glomerular filtration rate was measured by
plasma clearance of exogenous creatinine (Clcreat), exo- and endo-
iohexol (Clexo and Clendo), adapted from a protocol previously
proposed in cats [31]. Combined IV administration of iohexol and
creatinine has already been performed in dogs for renal and
plasma clearance procedures [32]. Briefly, a 15 mL baseline blood
sample was collected from the jugular vein (22 G needle) for basal
creatinine concentration. A 22 G catheter was placed in the
cephalic vein, 64.7 mg/kg (0.1 mL/kg) iohexol (Omnipaque 300,
GE Healthcare, Amersham Health, Wemmel, Belgium) was
injected, followed by 40 mg/kg of a creatinine solution and a
timer was started at the end of the injection. Afterwards, dead
space in the catheter was rinsed with 3 mL of sodium chloride
0.9%. The catheter was removed and 2.5 mL EDTA blood
samples were collected from the jugular vein at 5, 15, 60, 120, 240,
360 and 480 min after injection. Samples were centrifuged within
2 h and stored in aliquots of 300 mLa t220uC until assayed.
Plasma creatinine (Cr) concentrations were analysed using an
enzymatic method (Vettest 8008, Idexx, Hoofddorp, The Nether-
lands). This technique was validated by measuring samples with
increasing Cr concentration 4 times per day, on each of 3
consecutive days. The upper limit of quantification was
1202 mmol/L. Within- and between-day coefficients of variation
were ,3% in the lower, middle, and high concentration range (80,
530 and 1160 mmol/L, respectively), and there was linear
correlation between theoretical and measured concentrations
within quantification limits. The basal plasma Cr concentration
measured on the day of PEC-ICT testing was subtracted from the
Cr concentrations measured in the samples from that dog.
Plasma concentrations of iohexol stereo-isomers (exo- and endo-
iohexol) were determined by a validated high-performance liquid
chromatographic method with ultraviolet detection, as previously
described [33]. Percentage of exo- and endo-iohexol measured in
the iohexol solution were 83.4% and 16.6%, respectively. This
ratio was used to determine the dose of each isomer for clearance
calculations. Plasma concentrations below the limit of quantifica-
tion (LOQ) were not taken into account. The LOQ was 0.43 and
0.06 mg/ml for exo- and endo-iohexol, respectively.
Pharmacokinetic analyses were performed using WinNonlin
(WinNonlin version 4.0.1, Pharsight). For clearance calculation,
individual plasma data were subjected to noncompartmental
analysis, as described by Watson and coworkers [34]. The area
under the plasma Cr, exo- and endo-iohexol concentration versus
time curve (AUC) was calculated using the trapezoidal rule with
extrapolation to infinity. Plasma Clcreat,C l exo and Clendo were
determined by dividing the actually administered dose of
exogenous creatinine, exo- and endo-iohexol, respectively, by the
corresponding AUC, and indexation to bodyweight (mL/min/kg).
Serum and urinary renal markers
Serum Cr (sCr) (Vettest 8008, Idexx, Hoofddorp, The Nether-
lands) and urea (Roche hitachi, Roche diagnostics, Burgess Hill,
UK) were measured using an enzymatic method. Urinary protein
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chloride, and urinary creatinine with a modified Jaffe ´ reaction
using picric acid (Roche hitachi, Roche diagnostics, Burgess Hill,
UK). As markers of glomerular function, urinary (u) ALB and
uIgG concentrations were determined with a commercial canine
specific enzyme-linked immunosorbent assay (ELISA) (Immunol-
ogy Consultants Laboratory, Newberg, OR, USA). As an
indication of tubular function, uRBP was determined with a
human ELISA (Immunology Consultants Laboratory, Newberg,
OR, USA) and uNAG activity using a colorimetric assay (b-N-
Acetylglucosaminidase Assay kit, Sigma-Aldrich, St Louis, MO,
USA). All assays had been previously described and validated in
our laboratory [22,35]. Within- and between-day coefficients of
variation were 5.2 and 12.0% for the uALB ELISA, 6.1 and 7.7%
for the uIgG ELISA, 4.3 and 5.5% for the uRBP ELISA, and 4.9
and 8.1% for the uNAG colorimetric assay. Because spot urine
samples were used, urinary concentration of each marker was
indexed to urinary creatinine (c) and expressed as a ratio: uALB/c,
uIgG/c, uRBP/c and uNAG/c [36,37].
Kidney biopsies
Coagulation was checked in all dogs by measurement of buccal
mucosal bleeding time, and activated partial thromboplastin and
prothrombin time (CA 7000, Siemens, Brussels, Belgium).
Ultrasound guided percutaneous kidney biopsies were taken under
general anesthesia at T0, T16 wks and T24 wks. Dogs were
premedicated intravenously (IV) with a combination of acepro-
mazine (0.01 mg/kg) (Placivet, Codiphar, Wommelgem, Belgium)
and butorphanol (0.01 mg/kg) (Dolorex, Intervet NV, Mechelen,
Belgium). Afterwards, dogs received IV diazepam (0.2 mg/kg)
(Valium, Rosch, Brussels, Belgium) immediately followed by
propofol (Propovet, Abbott Animal Health, Queenborough, UK)
to effect until endotracheal intubation could be performed.
Anesthesia was maintained with isoflurane (2% vaporized in
100% oxygen) (Isoflo, Abbott Animal Health, Queenborough,
UK).
Ultrasound guided kidney biopsies were taken by an experi-
enced radiologist, according to a previously described technique
[38]. Large-bore 14-gauge needles with 9 cm length and 20 mm
specimen notch (Vet-CoreTM, Surgivet, USA) were used to take
two consecutive biopsies .10 mm long (or three biopsies
,10 mm long) from the left kidney. Biopsy cores were collected
and transported according to a standardized protocol adapted
from Lees and co-workers [39]. Specimens were transversely
divided in three parts and transferred into a standard container
with 3% glutaraldehyde for EM within 5 min after collection, in
10% buffered formalin for LM and in Michel’s transport medium
for IF. Biopsies were cooled and transported to a nephropathology
service within 24 h.
Three mm sections from each biopsy sample were stained with
hematoxylin and eosin (HE), periodic acid-Schiff (PAS), Masson’s
trichrome and periodic acid methenamine silver. All biochemical
stains were performed according to standard procedures [39].
Slides were evaluated using light microscopy for presence of
glomerular, tubular, interstitial and vascular lesions, using a tie-
grade system from 1 to 4 (1=rare lesion, 2=mild, 3=moderate,
4=severe).
For direct immunofluorescence (IF) examination, fresh unfixed
renal specimens were embedded in OCT compound, snap-frozen
in liquid nitrogen and stored at 280uC. Subsequently, 5 mm thick
sections were fixed with acetone for 15 min. After washing with
PBS (two passages), slides were incubated with FITC-labelled
sheep anti-dog IgG, goat anti-dog IgM, goat anti-dog IgA, goat
anti-dog C3 (all 4 from Bethyl Laboratories Inc., Montgomery,
TX, USA), rabbit anti-human k light chain, rabbit anti-human l
light chain, and rabbit anti-human complement factor C1Q (all 3
from Dako, Glostrup, Denmark). Primary antibodies were omitted
as negative controls and substituted with PBS [40]. Fluorescence
findings were classified according to the pattern seen on
immunofluorescent examination (granular or linear), which
included the localization of the deposit (mesangium, GBM, tubules
and vessels), the distribution (focal, diffuse, segmental and global)
and the intensity.
For transmission electron microscopy (EM), the tissue was post-
fixed in 2% osmium (in distilled water) for 1.5 h, dehydrated in
graded acetone and embedded in epon. Semi-thin sections were
stained with azure methylene blue. Ultrathin sections were
counterstained with uranyl acetate and lead citrate. For ultra-
structural studies, a Philips EM 420 was used. All histological
sections were examined in a blinded fashion by three pathologists.
Statistical analysis
Analyses were performed with a commercial software program
(Systat, version 12.00.08). Level of significance was set at 5%. A
Table 1. Glomerular filtration rate and routine renal markers in the control and hydrocortisone group.
Renal Marker T0 T16 wks T24 wks
Controls HC Controls HC Controls HC
Clcreat (mL/min/kg) 3.3 (2.8–3.7) 3.3 (2.6–3.7) 3.0 (2.1–3.4) 3.7 (2.5–4.2)* 2.8 (2.0–3.0) 2.7 (2.3–3.3)
Clexo (mL/min/kg) 2.9 (2.7–3.6) 3.2 (2.5–3.7) 2.9 (2.1–3.4) 4.0 (2.5–4.5)* 2.9 (2.1–3.1) 2.8 (2.0–3.3)
Clendo (mL/min/kg) 3.1 (2.8–3.9) 2.9 (2.3–4.5) 2.5 (1.6–2.9) 3.2 (1.8–3.9) 2.3 (1.8–2.4) 2.3 (1.6–2.7)
sCr (mmol/L) 72 (58–92) 80 (75–84) 86 (75–113) 88 (68–111) 90 (76–119) 90 (68–107)
urea (mmol/L) 13.1 (7.3–17.2) 11.0 (9.9–14.6) 10.3 (8.1–25.9) 9.2 (6.0–20.4) 11.8 (7.7–27.4) 10.8 (8.1–16.3)
USG 1.018 1.024 1.018 1,003 1,012 1.019
(1.008–1.035) (1.012–1.050) (1.011–1.020) (1.000–1.013) (1.006–1.050) (1.007–1.029)
UPC 1.77 (0.12–10)* 0.18 (0.13–1.56) 1.93 (0.11–6.55) 3.04 (0.28–6.19) 1.95 (0.15–6.67)* 0.16 (0.02–0.33)
T0, baseline; T16 wks, end of the 16 weeks hydrocortisone treatment period; T24 wks, 4 weeks after complete cessation of hydrocortisone treatment; HC,
hydrocortisone group; controls, control group; Clcreat, plasma clearance of creatinine; Clexo, plasma clearance of exo-iohexol, Clendo, plasma clearance of endoiohexol;
sCr, serum creatinine; USG, urinary specific gravity; UPC, urinary protein-to-creatinine ratio. The asterisk indicates in which group results are significantly increased
(p,0.05) compared to the other group at that timepoint.
doi:10.1371/journal.pone.0031702.t001
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time point and their interaction between the control and the HC
group. When a statistically significant interaction between
treatment and time point was detected, a post hoc hypothesis test
was performed to compare the two groups at each period.
Results
Induction of and recovery from hypercortisolism
All dogs assigned to the HC group developed clinical signs of
hypercortisolism, such as polyuria, polydipsia and skin changes
Figure 1. Plasma concentration versus time curves. Plasma creatinine (A1, A2), exo-iohexol (B1, B2) and endo-iohexol concentration (C1, C2)
versus time curves in the hydrocortisone (HC) group (6 dogs) and the control group (5 dogs) at T0, T16 wks and T24 wks. Mean 6 standard deviation
is displayed. The asterisk indicates a statistically significant difference (p,0.001) in plasma clearance between groups at T16 wks, for creatinine and
exo-iohexol clearance.
doi:10.1371/journal.pone.0031702.g001
Figure 2. Urinary markers. Median and 75-25
th percentiles of urinary albumin-to-creatinine ratio (uALBc) (A), immunoglobulin G-to-creatinine ratio
(uIgG/c) (B), retinol-binding protein-to-creatinine ratio (uRBP/c) (C) and N-acetyl-b-D-glucosaminidase ratio (uNAG/c) (D) at T0, T4 wks, T16 wks,
T20 wks and T24 wks in the hydrocortisone (HC) group (black circles) and in the control (C) group (white squares). The grey area indicates the
hydrocortisone administration period.
doi:10.1371/journal.pone.0031702.g002
Renal Effects of Hydrocortisone in Aged Dogs
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clipped haircoat, comedones, ecchymose) and complementary
laboratory changes (increased alkaline phosphatase and alanine
aminotransferase, ALT). Additionally, some dogs also developed
muscle atrophy and abdominal distention, but no significant
changes in bodyweight were detected throughout the study. At
T16 wks, 36 h after HC withdrawal, all dogs in the HC group
failed to respond adequately to ACTH-stimulation; median
(range) serum cortisol concentrations before and after ACTH-
injection were 18 nmol/L (6–30 nmol/L) and 25 nmol/L (17–
86 nmol/L). At T16 wks serum ALT was significantly increased in
the HC group compared to the control group (p,0.001).
At T24 wks,4 weeksaftercomplete HCwithdrawal,clinical signs
were resolved, except for skin changes in some dogs, and laboratory
changes returned to baseline (alkaline phosphatase and ALT within
reference interval). Response to an ACTH-stimulation test was
within normal range in all dogs; median (range) serum cortisol
concentrations before and after ACTH-injection were 32 nmol/L
(25–60 nmol/L) and 330 nmol/L (246–516 nmol/L).
Plasma exogenous creatinine-iohexol clearance test
As presented in Table 1, plasma Clcreat and Clexo were
significantly higher in the HC group than in the control group
at T16 wks (p,0.001). There was no significant difference
between groups either at baseline or at T24 wks. Plasma Clendo
was not significantly different between groups at any time point
(p=0.21). Figure 1 shows the plasma creatinine (A), exo-iohexol
(B) and endo-iohexol concentration (C) versus time curves in the
control and HC groups at baseline, T16 wks and T24 wks.
Serum and urinary renal markers
As shown in Table 1, no significant differences were detected
between groups for sCr (p=0.74), urea concentration (p=0.32)
and USG (p=0.30) throughout the study, despite a decrease of
USG during treatment in the HC group. Urinary protein-to-
creatinine ratio was significantly higher in the control group than
in the HC group (p=0.003) at baseline, T4 wks, T20 wks and
T24 wks, but not at T16 wks. Figure 2 presents the median and
75-25
th percentiles of UPC, uALB/c, uIgG/c, uRBP/c and
uNAG/c in the HC and control groups before, during and after
HC administration, with the grey area representing the treatment
period. Differences between HC and control groups in glomerular
markers uALB/c (p=0.05) and uIgG/c (p=0.26) did not reach
statistical significance, although they progressively increased
within the HC group during treatment and decreased afterwards.
Also for tubular markers uRBP/c (p=0.07) and uNAG/c
(p=0.20), there was no significant difference between the HC
and control groups at any time point, despite the fact that uRBP/c
seemed to increase within the HC group, with highest concentra-
tions at T16 wks, and declined again after discontinuation of HC.
Kidney histopathology
Most important light microscopic findings in HC and control
dogs are presented in Table 2 and 3. Affected dogs in both groups
and the score ranges of severity at different time points are
mentioned.
Commonly observed glomerular lesions were global endocapil-
lary and mesangial hypercellularity, with increase of mesangial
matrix. Increase of mesangial matrix progressed in both the HC
and control group at T16 wks and T24 wks, with an increasing
number of affected dogs and highest scores at T24 wks (Figure 3a,
3b and 3c). Obsolescent glomeruli were detected in one control
dog at T0, in 4 HC dogs and all control dogs at T16 wks, and in
all dogs at T24 wks (Figure 4a). Asymmetrical thickening and
splitting of Bowman’s capsule was most pronounced in two control
dogs especially at T24 wks, whereas only rare to mild changes
were seen in the HC group, mainly at T16 wks (Figure 4b).
Tubular lesions included tubular atrophy, tubular macro- and
micro-vesiculation and cellular pigment. In the HC group there
was no tubular atrophy at T0, whereas mild to severe atrophy was
detected in three dogs at T16 wks and T24 wks. Rare to moderate
tubular atrophy was present throughout the study in three to five
control dogs. At every time point, up to five HC dogs and all
control dogs had rare to moderate interstitial inflammation
Table 2. Glomerular lesions in the hydrocortisone (n=6 dogs) and control group (n=5 dogs).
Dog number
Global endocap.
hypercellularity
Prim. mesang.
hypercellularity
Diffuse
glomerulosclerosis
Global
glomerulosclerosis
Number of obsolescent
glomeruli
T0 T16 wks T24 wks T0 T1 wks T2 wks T0 T1 wks T24 wks T0 T1 wks T24 wks T0 T16 wks T24 wks
HC group
Dog 1 0 0 2 0 0 2 2 2 4 2 3 2 0 5/94 5/39
D o g 2 0 000 02 0 040 020 04 / 6 3
Dog 3 2 2 2 2 3 2 0 2 4 0 2 3 0 3/55 9/90
Dog 4 0 0 0 0 0 0 1 1 3 1 1 2 0 3/52 2/26
Dog 5 0 0 0 0 2 1 2 2 3 2 2 2 0 4/56 4/35
D o g 6 0 020 02 2 232 020 04 / 3 7
Control group
Dog 7 2 2 2 3 3 2 3 3 4 3 3 2 0 6/44 6/83
Dog 8 0 2 2 0 2 2 2 4 3 2 4 2 5/12 18/79 4/19
Dog 9 0 0 0 0 0 0 0 0 2 0 0 2 1/22 3/47 5/42
Dog 10 3 2 2 2 3 3 3 2 2 3 2 2 6/39 8/57 4/46
Dog 11 0 0 0 0 0 0 0 2 2 0 1 1 0 2/69 1/45
Endocap., endocapillary; Prim.mesang., primary mesangial; T0, baseline; T16 wks, end of the 16 weeks hydrocortisone treatment period; T24 wks, 4 weeks after
complete cessation of hydrocortisone treatment; HC, hydrocortisone. Score: 1=rare lesion, 2=mild, 3=moderate, 4=severe.
doi:10.1371/journal.pone.0031702.t002
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three HC dogs at T16 wks and T24 wks, and severe fibrosis in one
HC dog at T24 wks. Up to four control dogs had rare to mild
fibrosis at all time points.
Ultrastructural lesions included changes of the glomerular
basement membrane (GBM) such as thickening, rarefaction,
wrinkling and irregular jagged profile (Figure 5a). At T0, EM
detected GBM changes in only 2/6 HC dogs, but they were
Figure 3. Light microscopic lesions. (A) Glomerulus, Dog 11 at T0. Early glomerular lesions including minimal increase of mesangial matrix.
Periodic acid-Schiff staining (6400); (B) Glomerulus, Dog 11 at T16 weeks. Moderate hypercellularity of mesangial and endothelial cells and one
synechia. There is segmental to global increase of mesangial matrix and Bowman’s capsule is symmetrically thickened with proliferation of parietal
epithelial cells. Periodic acid-Schiff staining (6400); (C) Glomerulus, Dog 11 at T24 weeks. Moderate hypercellularity of mesangial and endothelial cells
associated with global increase of mesangial matrix. Visceral epithelial cells are hypertrophic. Periodic acid-Schiff staining (6400); (D) Tubulo-
interstitium, Dog 11 at T24 weeks. Moderate inflammation widely separating tubules and atrophic tubules. Periodic acid-methenamine silver staining
(6400).
doi:10.1371/journal.pone.0031702.g003
Table 3. Tubular and interstitial lesions in the hydrocortisone (n=6 dogs) and control group (n=5 dogs).
Dog number Tubular atrophy Tubular cell pigment Interstitial fibrosis Interstitial inflammation
T0 T16 wks T24 wks T0 T16 wks T24 wks T0 T16 wks T24 wks T0 T16 wks T24 wks
HC group
D o g 10 322 220 220 22
D o g 20 001 110 021 02
D o g 30 241 110 141 23
D o g 40 332 220 020 22
D o g 50 002 220 000 10
D o g 60 001 020 000 01
Control group
D o g 71 200 210 221 32
D o g 83 322 222 222 32
D o g 90 220 020 221 22
D o g 1 0 2 222 222 022 22
D o g 1 1 0 202 220 201 22
T0, baseline; T16 wks, end of the 16 weeks hydrocortisone treatment period; T24 wks, 4 weeks after complete cessation of hydrocortisone treatment; HC,
hydrocortisone. Score:
1=rare lesion, 2=mild, 3=moderate, 4=severe.
doi:10.1371/journal.pone.0031702.t003
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the control group mild to moderate GBM lesions were found at all
time points. Multifocal to diffuse podocyte foot process fusion was
found in 5/6 HC dogs and all five control dogs at every time point
(Figure 5b and 5c). Degenerative tubular cells and/or degenerative
changes in podocytes, endothelial and mesangial cells were
detected in dogs from both groups and were most pronounced
at T24 wks.
Due to a technical error concerning the Michel’s transport
medium, biopsies could not be evaluated with IF at T0.
Immunofluoresence staining at T16 wks and T24 wks was
unremarkable with coarse, segmental deposits of Ig G (1+ to 2+)
in the capillary wall in 1/6 HC dogs and 2/5 control dogs at
T16 wks. Mesangial Ig M deposits (1+ to 2+) were detected in 4/6
HC dogs and 3/5 control dogs at T16 wks, and in one control dog
at T24 wks. Coarse l light chain deposits (1+ to 2+) were seen in
the capillary walls and mesangium of one dog from each group at
T16 wks, and in one control dog at T24 wks. One dog from the
HC group had 1+ coarse, diffuse, segmental deposits of C3 at
T24 wks.
In summary, glomerular, tubular and interstitial lesions
presented in Table 2 and 3 progressed over time in both groups,
with most severe lesions detected at T24 wks. At T16 wks, a
marked increase was seen in the number of HC dogs with
obsolescent glomeruli and tubular atrophy compared to baseline.
No significant vascular changes (hypertrophic and hyaline
Figure 4. Glomerular lesions. (A) Glomerulus, Dog 8 at T16 weeks.
Obsolescent glomerulus. Periodic acid-Schiff staining (6400). (B)
Glomerulus, Dog 5 at T24 weeks. Accentuated lobulation, increase of
mesangial and endothelial cellularity of the tuft, and synechiae.
Splitting of Bowman’s capsule is visible. Periodic acid-Schiff staining
(6400).
doi:10.1371/journal.pone.0031702.g004
Figure 5. Electron microscopic glomerular lesions. (A) Glomer-
ulus, Dog 10 at T16 weeks. Sub-endothelial widening and rarefaction of
the glomerular basement membrane associated with foot process
effacement. EM 65000; (B) Glomerulus, Dog 9 at T24 weeks. Multifocal
foot process effacement (arrow) and endothelial cell swelling with
reduction of the capillary lumens and mesangial interposition (asterisk).
EM 64000; (C) Glomerulus, Dog 11 at T24 weeks. Diffuse and severe
foot process effacement (arrows). EM 64000.
doi:10.1371/journal.pone.0031702.g005
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present at baseline or at any of the other time points.
Discussion
This study demonstrates that HC administration reversibly
increases GFR in aged Beagle dogs. Plasma Clcreat and Clexo were
both significantly increased in the HC group at T16 wks, but no
longer differed between groups eight weeks after tapering and
cessation of treatment. This is in agreement with previous reports
showing that synthetic GC augment GFR in dogs, with an
increase in renal plasma flow (RPF), renal vasodilation and a
decrease in filtration fraction (FF) [5,41]. The mechanism for this
increase is most likely at least partly species-specific, since GC also
increase GFR in humans, but with little effect on RPF and an
increase instead of a decrease in FF [42]. Suggested mechanisms
include hemodynamic factors, interaction of GC with vaso-active
hormones and catabolic effects leading to an increase in plasma
amino acids, which in turn augments RPF and GFR [43,44].
Glucocorticoids can also mediate GFR changes through an
increased blood pressure, leading to a higher intraglomerular
pressure, although they do not always cause hypertension in dogs
[10]. However, blood pressure measurements were not available in
the current study.
Although all dogs included in the study were clinically healthy
with no abnormalities on hematology, biochemistry profile and
abdominal ultrasound, two dogs from the HC group and four dogs
from the control group had an increased UPC at baseline.
Proteinuria, which did not progress over a two year follow-up
period, has been previously described in otherwise healthy Beagles
by Stuart and coworkers [45]. In the latter study, LM and EM
changes were similar to our results and degree of proteinuria
correlatedwith theseverityofglomerular lesions[45].In the present
study, dogs with most severe glomerular changes also had the
highest UPC (nu 3: 1.56, nu 7: 1.77, nu 8: 10 and nu 10: 6.4;
reference range ,0.5). The dog with the highest UPC had severe
glomerulosclerosis and had the highest percentage of obsolescent
glomeruli throughout the study. Pre-existing renal lesions and
proteinuria, independent of GC administration, in these healthy
aged Beagle dogs raise questions for interpretation of similar
findings in dogs with glomerular diseases. Moreover, this important
observation has to be kept in mind when using Beagle dogs as a
model for human renal disease or toxicological studies [46].
Proteinuria was significantly higher in the control group than in
the HC group at all time points, except for T16 wks. This could be
caused by an increase in UPC in the HC group at the end of the
treatment period. Table 1 and Figure 2 indicate that UPC was
increased in the HC group at T16 wks and progressively
decreased again at T20 wks and T24 wks. Figure 2 also suggests
an increase followed by a decline within the HC group for uALB/
c, uIgG/c and uRBP/c, but not for uNAG/c. Nevertheless, dogs
with the highest UPC also had the highest uNAG/c, which could
be an indication of increased tubular lysosomal protein degrada-
tion. Interestingly, changes in the lysosomal degradation pattern
with altered distribution of lysosomes from the perinuclear to the
apical tubular cell region were also detected in proteinuric X-
linked Alport syndrome affected dogs [24].
Possible mechanisms causing glomerular proteinuria include
glomerular hypertension and structural alterations of the glomer-
ular barrier [47]. A GC-induced increase in GFR together with
hemodynamic alterations could augment glomerular pressure and
contribute to proteinuria. This hypothesis is supported by the
parallel increase of both GFR and proteinuria at the end of the
HC treatment period and their simultaneous decline after
cessation of treatment in the HC group. Structural alterations
that may contribute to proteinuria were glomerulosclerosis,
podocyte foot process effacement, and GBM changes such as
wrinkling, thickening, delamination and rarefaction. Whereas
proteinuria and hyperfiltration were rapidly reversible after
cessation of treatment in the HC group, the structural changes
seemed to persist at T24 wks. Possible explanations for this are
three-fold: 1) the lesions are not related to GC administration, but
are age-dependent and continue their physiological progression
over time, 2) the lesions are GC-induced and there is a longer lag-
time than eight weeks between tapering and cessation of HC
administration and normalization of structural changes, and 3) the
lesions are irreversible. Because it was not possible to repeat kidney
biopsies at a later time in the current Beagle colony, the present
study cannot confirm or dispute any of these hypotheses. It has
been previously demonstrated that serial cortical biopsies can be
obtained with minimal risk of inducing changes that might be
confused with those of a progressive renal disease [48]. Moreover,
ultrasound examination revealed healing of the needle tract lesions
within 2 to 3 weeks post-biopsy in both the HC and control group,
as also reported in literature [49]. Therefore, it is highly unlikely
that the renal lesions observed at T24 wks are a consequence of
repeated biopsy procedures.
At baseline, many dogs had mild to moderate pre-existing renal
lesions. Glomerulosclerosis has been described to be age-related in
dogs and in people [46,50]. Tubular atrophy, and interstitial
inflammation and fibrosis have also been shown to increase with
aging in both species [46,51,52]. The brownish cellular pigment
detected throughout the study in many dogs is most likely lipofuscin
accumulation, which again may be an age-related phenomenon as
previously suggested in rats and dogs [51,53]. Interestingly, no
vascular morphological changes were found throughout the current
study period in any of the groups, whereas in people vascular
changes are part of age-related renal lesions [54,55].
At the end of the HC administration period, most striking LM
findings in the HC group, not detected at baseline, were
obsolescent glomeruli and tubular atrophy. However, there was
a higher prevalence of renal lesions at baseline than expected and
glomerular, tubular and interstitial changes also progressed in the
control group. Therefore, it is not possible to separate HC effects
from progression of pre-existing renal lesions. It is possible that
HC administration accelerated age-related glomerulosclerotic and
tubular changes in the HC group, but definitive conclusions
cannot be drawn from these data. Another limitation of the study
is the lack of IF examination at baseline. However, IF findings at
T16 wks and T24 wks were either mild or non-specific. For
example, the mesangial IgM deposits detected in some HC and
control dogs at T16 wks and in one control dog at T24 wks were
probably due to entrapment of IgM in sclerotic glomeruli.
In conclusion, this study shows that HC administration
reversibly increases GFR, with a similar trend for proteinuria.
Results indicate that clinically healthy aged Beagle dogs have renal
lesions and proteinuria, which could have implications for
experimental or toxicological studies. Although further research
is needed to elucidate whether morphological renal changes are
GC-induced, hyperfiltration and proteinuria are, and warrant
attention to kidney function in human and canine patients with
Cushing’s syndrome or receiving exogenous GC.
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